Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Ginkgo Bioworks Holdings's EV-to-OCF or its related term are showing as below:
DNA'
s EV-to-OCF Range Over the Past 10 Years
Min: -114.38 Med: -4.95 Max: -0.04
Current: -3.18
During the past 7 years, the highest EV-to-OCF of Ginkgo Bioworks Holdings was -0.04. The lowest was -114.38. And the median was -4.95.
DNA's EV-to-OCF is ranked worse than 51.67% of 1409
companies
in the Biotechnology industry
Industry Median: -3.6
vs DNA: -3.18
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Ginkgo Bioworks Holdings's PE Ratio (TTM) for today is calculated as:
Ginkgo Bioworks Holdings's share price for today is $6.53.
Ginkgo Bioworks Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.010.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Ginkgo Bioworks Holdings EV-to-OCF Related Terms
Ginkgo Bioworks Holdings EV-to-OCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Ginkgo Bioworks Holdings's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ginkgo Bioworks Holdings EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ginkgo Bioworks Holdings's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Ginkgo Bioworks Holdings's EV-to-OCF falls into.
Ginkgo Bioworks Holdings's current Enterprise Value is $541.7 Mil.
Ginkgo Bioworks Holdings's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-170.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ginkgo Bioworks Holdings (DNA) has a EV-to-OCF of -3.18 as of Aug. 19, 2026. According to the industry distribution chart, Ginkgo Bioworks Holdings ranks #728 out of 1409 companies in the Biotechnology industry, placing it in the top 51.7%.
Is Ginkgo Bioworks Holdings' EV-to-OCF too high?
Ginkgo Bioworks Holdings' current EV-to-OCF is -3.18. Based on the distribution chart, Ginkgo Bioworks Holdings ranks #728 out of 1409 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Ginkgo Bioworks Holdings has a GF Score™ of 60/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ginkgo Bioworks Holdings' EV-to-OCF compare to RZLT and EIKN?
According to the Biotechnology industry distribution chart, Ginkgo Bioworks Holdings ranks #728 out of 1409 companies for EV-to-OCF. This places Ginkgo Bioworks Holdings in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Ginkgo Bioworks Holdings's current EV-to-OCF is -3.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ginkgo Bioworks Holdings stock overvalued right now?
Based on GuruFocus' analysis, Ginkgo Bioworks Holdings (DNA) is currently considered Fairly Valued. The stock's GF Value™ is $5.96, compared to a current price of $6.53 — trading 9.6% above its estimated fair value. The current EV-to-OCF is -3.18. Ginkgo Bioworks Holdings' overall GF Score™ is 60/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Ginkgo Bioworks Holdings (DNA), the current EV-to-OCF is -3.18 as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ginkgo Bioworks Holdings (DNA) Overvalued in 2026?
Based on GuruFocus' analysis, Ginkgo Bioworks Holdings stock appears to be overvalued.
The current stock price of $6.53 is trading 9.6% above its estimated GF Value™ of $5.96.
GuruFocus considers Ginkgo Bioworks Holdings to be Fairly Valued.
Key valuation signals for DNA:
EV-to-OCF: -3.18
GF Value™: $5.96 vs. price of $6.53 (9.6% above fair value)
No single metric tells the full story. See the DNA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.
60GF Score
Get the complete analysis for DNA
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DNA has been successfully added to your 
